The effects of ML 3000 on antigen-induced responses in sheep

W. M. Abraham, S. Laufer, S. Tries

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

ML 3000 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO), two enzymes that contribute to the airway inflammation in asthma. When administered as an aerosol at a dose of 100 mg, 0.5 h before antigen challenge in allergic sheep, ML 3000 provided significant inhibition against the early bronchial response (EAR, mean 33% protection, P < 0.05), completely blocked the late antigen-induced bronchoconstriction (LAR, mean 81% protection, P < 0.05) and the airway hyperresponsiveness (AHR, P < 0.05) to aerosolized carbachol that occurs 24 h after antigen challenge in this model. Consistent with this functional protection was a small but significant reduction in the percentage of neutrophils recovered in bronchoalveolar lavage (BAL) at 8 h and 24 h after challenge. These findings are similar to previous data obtained in this animal model with other 5-LO inhibitors (blockade of the LAR and AHR) and COX inhibitors (blockade of AHR). These results suggest that aerosol administration of a dual inhibitor of COX and 5-LO may have beneficial effects in the treatment of allergic airway disease.

Original languageEnglish
Pages (from-to)167-173
Number of pages7
JournalPulmonary Pharmacology and Therapeutics
Volume10
Issue number3
DOIs
StatePublished - Jun 1 1997
Externally publishedYes

Fingerprint

licofelone
Lipoxygenase Inhibitors
Cyclooxygenase Inhibitors
Arachidonate 5-Lipoxygenase
Sheep
Aerosols
Antigens
Bronchoconstriction
Carbachol
Bronchoalveolar Lavage
Animals
Neutrophils
Asthma
Animal Models
Inflammation
Enzymes

Keywords

  • 5-lipoxygenase
  • Asthma
  • Bronchoconstriction
  • Cyclooxygenase
  • Late response
  • Therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Cite this

The effects of ML 3000 on antigen-induced responses in sheep. / Abraham, W. M.; Laufer, S.; Tries, S.

In: Pulmonary Pharmacology and Therapeutics, Vol. 10, No. 3, 01.06.1997, p. 167-173.

Research output: Contribution to journalArticle

Abraham, W. M. ; Laufer, S. ; Tries, S. / The effects of ML 3000 on antigen-induced responses in sheep. In: Pulmonary Pharmacology and Therapeutics. 1997 ; Vol. 10, No. 3. pp. 167-173.
@article{4615c62aaa814b4dafbcd913bb1253e0,
title = "The effects of ML 3000 on antigen-induced responses in sheep",
abstract = "ML 3000 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO), two enzymes that contribute to the airway inflammation in asthma. When administered as an aerosol at a dose of 100 mg, 0.5 h before antigen challenge in allergic sheep, ML 3000 provided significant inhibition against the early bronchial response (EAR, mean 33{\%} protection, P < 0.05), completely blocked the late antigen-induced bronchoconstriction (LAR, mean 81{\%} protection, P < 0.05) and the airway hyperresponsiveness (AHR, P < 0.05) to aerosolized carbachol that occurs 24 h after antigen challenge in this model. Consistent with this functional protection was a small but significant reduction in the percentage of neutrophils recovered in bronchoalveolar lavage (BAL) at 8 h and 24 h after challenge. These findings are similar to previous data obtained in this animal model with other 5-LO inhibitors (blockade of the LAR and AHR) and COX inhibitors (blockade of AHR). These results suggest that aerosol administration of a dual inhibitor of COX and 5-LO may have beneficial effects in the treatment of allergic airway disease.",
keywords = "5-lipoxygenase, Asthma, Bronchoconstriction, Cyclooxygenase, Late response, Therapy",
author = "Abraham, {W. M.} and S. Laufer and S. Tries",
year = "1997",
month = "6",
day = "1",
doi = "10.1006/pupt.1997.0090",
language = "English",
volume = "10",
pages = "167--173",
journal = "Pulmonary Pharmacology and Therapeutics",
issn = "1094-5539",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - The effects of ML 3000 on antigen-induced responses in sheep

AU - Abraham, W. M.

AU - Laufer, S.

AU - Tries, S.

PY - 1997/6/1

Y1 - 1997/6/1

N2 - ML 3000 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO), two enzymes that contribute to the airway inflammation in asthma. When administered as an aerosol at a dose of 100 mg, 0.5 h before antigen challenge in allergic sheep, ML 3000 provided significant inhibition against the early bronchial response (EAR, mean 33% protection, P < 0.05), completely blocked the late antigen-induced bronchoconstriction (LAR, mean 81% protection, P < 0.05) and the airway hyperresponsiveness (AHR, P < 0.05) to aerosolized carbachol that occurs 24 h after antigen challenge in this model. Consistent with this functional protection was a small but significant reduction in the percentage of neutrophils recovered in bronchoalveolar lavage (BAL) at 8 h and 24 h after challenge. These findings are similar to previous data obtained in this animal model with other 5-LO inhibitors (blockade of the LAR and AHR) and COX inhibitors (blockade of AHR). These results suggest that aerosol administration of a dual inhibitor of COX and 5-LO may have beneficial effects in the treatment of allergic airway disease.

AB - ML 3000 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO), two enzymes that contribute to the airway inflammation in asthma. When administered as an aerosol at a dose of 100 mg, 0.5 h before antigen challenge in allergic sheep, ML 3000 provided significant inhibition against the early bronchial response (EAR, mean 33% protection, P < 0.05), completely blocked the late antigen-induced bronchoconstriction (LAR, mean 81% protection, P < 0.05) and the airway hyperresponsiveness (AHR, P < 0.05) to aerosolized carbachol that occurs 24 h after antigen challenge in this model. Consistent with this functional protection was a small but significant reduction in the percentage of neutrophils recovered in bronchoalveolar lavage (BAL) at 8 h and 24 h after challenge. These findings are similar to previous data obtained in this animal model with other 5-LO inhibitors (blockade of the LAR and AHR) and COX inhibitors (blockade of AHR). These results suggest that aerosol administration of a dual inhibitor of COX and 5-LO may have beneficial effects in the treatment of allergic airway disease.

KW - 5-lipoxygenase

KW - Asthma

KW - Bronchoconstriction

KW - Cyclooxygenase

KW - Late response

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0031172919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031172919&partnerID=8YFLogxK

U2 - 10.1006/pupt.1997.0090

DO - 10.1006/pupt.1997.0090

M3 - Article

C2 - 9514627

AN - SCOPUS:0031172919

VL - 10

SP - 167

EP - 173

JO - Pulmonary Pharmacology and Therapeutics

JF - Pulmonary Pharmacology and Therapeutics

SN - 1094-5539

IS - 3

ER -